Camlin Fine Sciences

Mumbai, India Founded: 1931 • Age: 95 yrs Listed
Manufacturer of fine chemicals catering to food industry
Request Access
Report Incorrect Data
Page last updated

About Camlin Fine Sciences

Camlin Fine Sciences is a publicly listed company based in Mumbai (India) founded in 1931. Manufacturer of fine chemicals catering to food industry. The company has 693 employees. Camlin Fine Sciences has completed 2 acquisitions, including Dresen and Vinpai. Its chief executive, as recorded, is Ashish Subhash Dandekar. Its website camlinfs.com draws about 21 thousand monthly visits. Its Indian entity Camlin Fine Sciences Limited reported revenue of ₹1,809 Cr. Camlin Fine Sciences offers products and services including Xtendra, Nasure, Ezential, adorr, and Dinamic. Its focus areas include Chemicals and Materials, Diversified Chemicals and Diversified.

Company details

Camlin Fine Sciences (earlier Camlin Fine Chemicals) offers food grade antioxidants for the food and feed market. Camlins main products are TBHQ, BHA and ascorbyl palmitate for fats and oils. Apart, it also has a product range that includes liquid antioxidant blends (synthetics and naturals), food-grade ingredients and industrial antioxidants.

  • Headquarters Mumbai, India
  • Employees 693
  • Stage Public
  • Sectors
    Chemicals & Materials
  • Website camlinfs.com
  • Social LinkedIn
  • Legal Name Camlin Fine Sciences Limited
Operational Areas
Chemicals & Materials → Core & Diversified Chemicals
Key Metrics
  • Market Cap
    ₹1,509 Cr

    CAMLINFINE · NSE

  • Share Price
    ₹79.24

    +0.90% today

  • Revenue
    ₹1,723 Cr

    FY 2025-26 · +5.8% YoY

  • EBITDA
    ₹91.39 Cr

    Margin 5.3%

  • Net Profit
    ₹36.46 Cr

    FY 2025-26 · +127.8% YoY

  • ROE
    3.3%

    ROCE 4.7%

  • Debt / Equity
    0.71

    Interest cover 404.9x

  • Latest Funding Round
    $18.82M (USD), Post-IPO

    Feb 2022

  • Investors
    Convergent Finance

    & 1 more

  • Employee Count
    693
  • Investments & Acquisitions
    Dresen

    & 1 more

Products & Services of Camlin Fine Sciences

Camlin Fine Sciences offers a comprehensive portfolio of products and services, including Xtendra, Nasure, Ezential, adorr, and Dinamic.

Xtendra
Specialty Ingredients

Provides food safety and protection solutions

Nasure
Antioxidant Solutions

Offers plant-based shelf-life extension for food

Ezential
Functional Ingredients

Delivers functional excellence for food industry

adorr
Aroma Ingredients

Focuses on vanillin range for fragrances

Dinamic
Performance Chemicals

Supplies diphenols for petrochemicals and pharmaceuticals

Biosus
Sustainable Ingredients

Produces vegan DHA for nutrition and health

Funding Insights of Camlin Fine Sciences

  • Total Rounds 2
  • Last Round Post-IPO — $18.82M
  • First Round $23.8M

    (Jun 2020)

  • Investors Count 2

All 2 funding rounds of Camlin Fine Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2022$18.82MPost-IPO––
Infinity Direct Holdings
Jun 2020$23.8MPost-IPO––
Convergent
Valuation history

2 investors in total: 2 institutional.

Investors in Camlin Fine Sciences

Camlin Fine Sciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Infinity Direct Holdings and Convergent Finance.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Infinity Direct Holdings
Multiple sectors are invested in by this private equity firm.
Ebene City, Mauritius
Convergent Finance
Convergent Finance is engaged in private equity investments in India.
convergentfinance.comMumbai, India
Premium access

Investor details for Camlin Fine Sciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Camlin Fine Sciences Limited (Camlin Fine Sciences)

Camlin Fine Sciences Limited is the primary company behind Camlin Fine Sciences. The board of Camlin Fine Sciences Limited currently have 12 directors; the longest-serving is Ashish Subhash Dandekar, appointed in 2007. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ashish Subhash Dandekar
DIN 01077379
Managing Director11 Jan 200719 yrs 9 moCamlin Fine Sciences Limited
Nirmal Vinod Momaya
DIN 01641934
Managing Director04 Aug 201412 yrs 3 moCamlin Fine Sciences Limited
Anagha Subhash Dandekar
DIN 07897205
Director28 Aug 20179 yrs 2 moCamlin Fine Sciences Limited
Arjun Sudhakar Dukane
DIN 06820240
Whole-time director01 Jun 20188 yrs 5 moCamlin Fine Sciences Limited
Amol Jashvant Shah
DIN 00171006
Director02 Aug 20197 yrs 3 moCamlin Fine Sciences Limited
Harsha Raghavan
DIN 01761512
Director10 Aug 20206 yrs 3 moCamlin Fine Sciences Limited
Josephconrad Agnelo Dsouza
DIN 00010576
Director28 Sep 20206 yrs 1 moCamlin Fine Sciences Limited
Mahabaleshwar Ganpat Palekar
DIN 02455892
Director24 Dec 20205 yrs 10 moCamlin Fine Sciences Limited
Pradip Manilal Kanakia
DIN 00770347
Director18 Oct 20215 yrsCamlin Fine Sciences Limited
Abeezar Ebrahim Faizullabhoy
DIN 00264422
Director04 Feb 20251 yr 9 moCamlin Fine Sciences Limited
Radhika Madhukar Dudhat
DIN 00016712
Director12 Mar 20251 yr 8 moCamlin Fine Sciences Limited
Jens Van Nieuwenborgh
DIN 07638244
Director12 Mar 20251 yr 8 moCamlin Fine Sciences Limited

People of Camlin Fine Sciences

61 people are tracked at Camlin Fine Sciences (20 in leadership, 8 in board & advisors, 33 in team); the tracked headcount is 693.

NameRoleGroup
Ashish Subhash Dandekar
CEOLeadership
Nirmal Vinod Momaya
Managing DirectorLeadership
Arjun Dukane
Executive Director, TechnicalLeadership
Sameer Thakur
General Manager (process Development)Leadership
Dr. Chandrakant Ghotekar
Associate Vice PresidentLeadership
Sushant Bhingarde
General Manager- Project ProcurementLeadership
Raghunath Bal
Global Head ITLeadership
Bhushan Patil
Deputy General ManagerLeadership
Neeti Chavan
Technical Head (food Division)Leadership
Dr. Rashid Nadaf
Sr. Principal Scientist And R&d HeadLeadership
Mahendra Tripathi
National Sales Head ( Food & Blends)Leadership
Anvarhusen Bilakhiya
Vice President Research And DevelopmentLeadership
Sangeetha Srinivasan
Vice President Health & WellnessLeadership
Xaviour Paul
Vice President Supply ChainLeadership
Udit Ghote
Assistant General Manager-projectsLeadership
Kiran Jadhav
Head Supply Chain (avp) At Camlin Fine Sciences LimitedLeadership
Krishna Daulat
Assistant General Manager - Supply Chain And Sales CoordinationLeadership
Shaju Vaikathukattil Ashokan
Technical HeadLeadership
Dinesh Sharma
Vice President- Technical Sales ( South Asia ) Food Div. In Camlin Fine Sciences Ltd.Leadership
Sameer Khedkar
Vice President - Special ProjectsLeadership

41 more people are available in the full profile.

Premium access

Complete people profiles for Camlin Fine Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Camlin Fine Sciences

Camlin Fine Sciences is a publicly listed company on the NSE with ticker symbol CAMLINFINE in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Jan 2015
  • Listed onNSE: CAMLINFINE
  • Listed entityCamlin Fine Sciences Limited
  • Exchange sectorProcess industries
  • ISININE052I01032
  • Share price₹89.79 (-1.09% on the day) · 2026-10-14
  • Market capitalisation₹1,746 Cr
  • Price to earnings419.0
  • EPS (diluted, trailing year)₹0.21
  • Volume (last session)505,737

Financials of Camlin Fine Sciences

Exchange-reported figures of Camlin Fine Sciences Limited, the listed company behind Camlin Fine Sciences (NSE: CAMLINFINE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,723 Cr
+5.8% YoY
EBITDA
₹91.39 Cr
+1486.8% YoY
Profit After Tax
₹36.46 Cr
+127.8% YoY
Net Worth
₹1,041 Cr
+15.4% YoY
Total Assets
₹1,729 Cr
+12.8% YoY
Total Debt
₹720 Cr
+10.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7231,6291,4541,6821,4121,1871,049
Revenue growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%-
EBITDA91.39(6.59)11.52201158187135
EBITDA margin+5.3%-0.4%+0.8%+12.0%+11.2%+15.7%+12.9%
Profit before tax23.11(159)(99.24)80.3893.9710558.21
Net profit36.46(131)(92.64)56.9460.8350.9530.33
Net profit margin+2.1%-8.1%-6.4%+3.4%+4.3%+4.3%+2.9%
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
Balance sheet
Total assets1,7291,5331,5461,6301,4361,2661,001
Net worth1,041902865819748643403
Total debt720652683801646550539
Cash & bank15315493.5399.2314213864.79
Net working capital643658602673540585444
Cash flow
Cash from operations82.0723.0013950.9014511786.02
Cash from investing(52.95)(75.35)(66.50)(125)(249)(133)(90.12)
Cash from financing(24.63)76.17(85.97)59.6613638.633.25
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue491520425441450408432431
Revenue growth (YoY)+9.2%+27.5%-1.6%+2.2%+7.9%+7.1%--
Other income5.322.741112.684.267.5212.971.34
EBITDA(1.31)(3.66)13.24(6.30)22.1912.7626.9046.88
EBITDA margin-0.3%-0.7%+3.1%-1.4%+4.9%+3.1%+6.2%+10.9%
Depreciation19.9219.1620.8216.3217.6616.1317.1414.48
Interest20.5914.0122.9817.2617.8514.8614.9334.07
Profit before tax(36.50)(34.09)80.04(37.20)(9.06)(10.71)7.80(0.33)
Tax(6.81)(0.46)(6.24)(0.09)5.89(0.02)7.697.14
Net profit(29.69)(33.63)86.28(37.11)(14.95)(10.69)0.11(7.47)
EPS (₹)(1.45)(1.65)4.54(2.38)(0.76)(0.53)(1.24)(0.71)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue838886773789686600580
Revenue growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%-
EBITDA39.74(16.41)32.7213380.4465.2059.83
EBITDA margin+4.7%-1.9%+4.2%+16.9%+11.7%+10.9%+10.3%
Profit before tax(54.09)(123)(59.64)66.6236.0715.0341.28
Net profit(15.42)18.41(49.07)47.7325.868.5533.10
Net profit margin-1.8%+2.1%-6.4%+6.1%+3.8%+1.4%+5.7%
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
Balance sheet
Total assets1,4181,2961,2321,2641,056846721
Net worth929862716642592465377
Total debt482428511617461378340
Cash & bank80.8984.6513.959.8356.4881.5913.12
Net working capital565558527561441444342
Cash flow
Cash from operations43.9618.1482.1018.5246.8026.0273.90
Cash from investing(30.40)(87.66)(51.72)(115)(172)(88.00)(66.03)
Cash from financing(13.41)105(34.05)78.3912980.05(26.06)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue245222184219244191273205
Revenue growth (YoY)+0.2%+16.2%-32.7%+6.8%+7.6%+5.2%--
Other income4.541.4015.305.7710.193.699.206.82
Total expenses251216180214226187239189
EBITDA(6.43)6.823.405.3418.204.6833.2716.39
EBITDA margin-2.6%+3.1%+1.9%+2.4%+7.5%+2.4%+12.2%+8.0%
Depreciation13.7913.5113.2913.5113.4713.4013.1313.26
Interest15.4913.3822.0514.8618.7311.3417.4417.15
Profit before tax(31.17)(18.67)(16.64)(17.26)(3.81)(16.37)11.90(7.20)
Tax(11.17)(6.36)(10.99)(4.27)(0.17)(5.70)(3.72)(1.57)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue491520425441450408432431
Revenue growth (YoY)+9.2%+27.5%-1.6%+2.2%+7.9%+7.1%--
Other income5.322.741112.684.267.5212.971.34
EBITDA(1.31)(3.66)13.24(6.30)22.1912.7626.9046.88
EBITDA margin-0.3%-0.7%+3.1%-1.4%+4.9%+3.1%+6.2%+10.9%
Depreciation19.9219.1620.8216.3217.6616.1317.1414.48
Interest20.5914.0122.9817.2617.8514.8614.9334.07
Profit before tax(36.50)(34.09)80.04(37.20)(9.06)(10.71)7.80(0.33)
Tax(6.81)(0.46)(6.24)(0.09)5.89(0.02)7.697.14
Net profit(29.69)(33.63)86.28(37.11)(14.95)(10.69)0.11(7.47)
EPS (₹)(1.45)(1.65)4.54(2.38)(0.76)(0.53)(1.24)(0.71)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7231,6291,4541,6821,4121,1871,049
Revenue growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%-
Other income85.5315.6015.555.8033.034.983.43
Total expenses1,6321,6351,4421,4801,2541,000914
Employee cost24418515316314512099.71
EBITDA91.39(6.59)11.52201158187135
EBITDA margin+5.3%-0.4%+0.8%+12.0%+11.2%+15.7%+12.9%
Depreciation70.9260.9656.3562.5155.9644.2932.80
Interest82.8910769.9664.1840.8042.4847.63
Profit before tax23.11(159)(99.24)80.3893.9710558.21
Tax(0.46)(0.51)5.6340.5733.6039.7428.37
Net profit36.46(131)(92.64)56.9460.8350.9530.33
Net profit margin+2.1%-8.1%-6.4%+3.4%+4.3%+4.3%+2.9%
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.2118.7916.7515.7115.7012.7512.13
Reserves & surplus1,018880845800729582388
Shareholders' funds (net worth)1,041902865819748643403
Minority interest(40.07)(26.89)(7.80)4.7117.1269.7556.97
Secured loans624529520613411283326
Unsecured loans96.00122163188235267213
Total debt720652683801646550539
Total liabilities1,7291,5331,5461,6301,4361,2661,001
Assets
Gross block1,3271,2711,1691,124816753430
Net block887704816858601584306
Capital work in progress32.859.7345.8743.0221523.82179
Investments30.2660.987.887.967.237.367.36
Inventories504527540568371320298
Sundry debtors373328285305300271253
Cash & bank balances15315493.5399.2314213864.79
Loans & advances20413610911680.8765.6559.21
Total current assets1,2341,1451,0281,088894795675
Total current liabilities591488426415354209230
Net working capital643658602673540585444
Total assets1,7291,5331,5461,6301,4361,2661,001
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10480.2593.7410875.5252.3753.21
Net cash from operating activities82.0723.0013950.9014511786.02
Net cash from investing activities(52.95)(75.35)(66.50)(125)(249)(133)(90.12)
Net cash from financing activities(24.63)76.17(85.97)59.6613638.633.25
Net change in cash4.4823.82(13.49)(14.07)32.2923.15(0.85)
Closing cash15315493.5399.2314213864.79
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%-
EBITDA growth+1486.8%-157.2%-94.3%+27.6%-15.6%+38.2%-
PBT growth+9998.0%-59.8%--14.5%-10.6%+80.6%+248.6%
Net income growth+127.8%-41.7%-262.7%-6.4%+19.4%+68.0%-
Revenue CAGR (3Y)+0.8%+4.9%+7.0%+17.0%+16.5%+18.1%+25.3%
EBITDA CAGR (3Y)-23.1%--60.5%+14.2%+29.4%+126.9%+61.9%
Profitability & leverage
Net income margin+1.4%-9.7%-7.2%+2.4%+4.3%+5.5%+2.8%
Return on capital employed+4.7%+11.9%+8.4%+10.7%+11.1%+14.5%+11.9%
Return on net worth+3.3%-17.5%-13.3%+6.3%+10.0%+13.8%+7.7%
Debt / equity0.710.780.941.020.991.151.29
Long-term debt / equity0.320.370.490.580.570.530.54
Interest cover404.93-157.93-156.0646.2540.1029.7946.51
Efficiency & per share
Fixed asset turnover1.331.361.331.872.042.192.66
Inventory turnover3.343.052.623.584.093.843.60
Debtors turnover4.925.314.935.574.954.544.54
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)54.0147.8148.7647.8842.1738.7532.97
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue245222184219244191273205
Revenue growth (YoY)+0.2%+16.2%-32.7%+6.8%+7.6%+5.2%--
Other income4.541.4015.305.7710.193.699.206.82
Total expenses251216180214226187239189
EBITDA(6.43)6.823.405.3418.204.6833.2716.39
EBITDA margin-2.6%+3.1%+1.9%+2.4%+7.5%+2.4%+12.2%+8.0%
Depreciation13.7913.5113.2913.5113.4713.4013.1313.26
Interest15.4913.3822.0514.8618.7311.3417.4417.15
Profit before tax(31.17)(18.67)(16.64)(17.26)(3.81)(16.37)11.90(7.20)
Tax(11.17)(6.36)(10.99)(4.27)(0.17)(5.70)(3.72)(1.57)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue838886773789686600580
Revenue growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%-
Other income35.0320.6218.8828.8318.705.4724.06
Total expenses798903741656605535520
Employee cost75.9872.4866.2860.1953.3238.8728.18
EBITDA39.74(16.41)32.7213380.4465.2059.83
EBITDA margin+4.7%-1.9%+4.2%+16.9%+11.7%+10.9%+10.3%
Depreciation53.6852.5349.3932.8226.6819.2811.28
Interest75.1875.1261.8562.3936.3936.3631.33
Profit before tax(54.09)(123)(59.64)66.6236.0715.0341.28
Tax(21.13)(47.12)(8.24)19.0710.216.7410.56
Net profit(15.42)18.41(49.07)47.7325.868.5533.10
Net profit margin-1.8%+2.1%-6.4%+6.1%+3.8%+1.4%+5.7%
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.2118.7916.7515.7115.7012.7512.13
Reserves & surplus906840696623573403361
Shareholders' funds (net worth)929862716642592465377
Secured loans442412458535328261223
Unsecured loans39.8315.8652.9882.07132117117
Total debt482428511617461378340
Total liabilities1,4181,2961,2321,2641,056846721
Assets
Gross block756755717682381347134
Net block52656957758330429495.64
Capital work in progress22.709.1031.4428.3620718.44198
Investments21710279.8781.8081.7873.5674.02
Inventories24426325525214213197.22
Sundry debtors474414492526441368323
Cash & bank balances80.8984.6513.959.8356.4881.5913.12
Loans & advances12112999.8287.6280.9276.8177.35
Total current assets919891860876721658511
Total current liabilities354333333315279214169
Net working capital565558527561441444342
Total assets1,4181,2961,2321,2641,056846721
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash36.070.684.3522.1718.780.7018.89
Net cash from operating activities43.9618.1482.1018.5246.8026.0273.90
Net cash from investing activities(30.40)(87.66)(51.72)(115)(172)(88.00)(66.03)
Net cash from financing activities(13.41)105(34.05)78.3912980.05(26.06)
Net change in cash0.1535.39(3.67)(17.82)3.3918.08(18.19)
Closing cash80.8984.6513.959.8356.4881.5913.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%-
EBITDA growth+342.2%-150.2%-75.4%+65.3%+23.4%+9.0%-
PBT growth+56.2%-107.0%-+84.7%+140.0%-63.6%+190.9%
Net income growth-183.8%+137.5%-202.8%+84.6%+202.5%-74.2%-
Revenue CAGR (3Y)+2.0%+9.0%+8.8%+10.8%+7.7%+14.2%+21.3%
EBITDA CAGR (3Y)-33.2%--20.5%+30.5%+34.7%+103.0%+34.8%
Profitability & leverage
Net income margin-3.9%-8.6%-6.7%+6.0%+3.8%+1.4%+5.3%
Return on capital employed+2.9%+3.8%+0.2%+11.1%+7.6%+6.6%+10.5%
Return on net worth-1.7%+2.3%-7.6%+7.7%+4.9%+2.0%+8.5%
Debt / equity0.510.600.830.870.790.850.90
Long-term debt / equity0.220.270.400.460.410.340.32
Interest cover-539.31-108.96-371.0362.2867.6979.1864.53
Efficiency & per share
Fixed asset turnover1.111.201.111.491.882.494.73
Inventory turnover3.313.423.054.005.015.255.61
Debtors turnover1.891.961.521.631.701.741.98
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)48.1845.7142.5440.6737.5232.5930.80

Investments & Acquisitions by Camlin Fine Sciences

Camlin Fine Sciences has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Dresen and Vinpai.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Vinpai
Food ingredients processing, cosmetics, and medical services are provided.
vinpai.com2011Feb 2025••••
Dresen
Traditional antioxidants are manufactured by Dresen in Mexico City.
dresen.com.mxMexico1980Feb 2016$8.5M
Premium access

Complete acquisition details for Camlin Fine Sciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Camlin Fine Sciences

6 dated milestones of Camlin Fine Sciences across 94 years, from founding to its latest funding, stage changes and deals.

  1. Founded Camlin Fine Sciences is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Dresen.
  4. Funding First funding round of $23.8M.
  5. Funding Latest funding round, Post-IPO, of $18.8M.
  6. Acquisition Acquires Vinpai.

Web traffic of Camlin Fine Sciences

The website of Camlin Fine Sciences (camlinfs.com) receives about 21K visits a month.

  • Monthly visits
    21K

    ▼ 9.2% vs previous month

Similar websites

Websites whose visitors overlap most with Camlin Fine Sciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Kokuyo Camlin
kokuyocamlin.com
25%
76.8K#414,605View details

Top companies in Core & Diversified Chemicals

3 companies that operate in the same segment as Camlin Fine Sciences (Core & Diversified Chemicals) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
DFPCL
Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate
1979Pune, Maharashtra, IndiaUSD 1.21 B1,020
Scimplify
Specialty chemicals are manufactured through integrated R&D and production processes.
2023Bengaluru, Karnataka, IndiaUSD 72.97 MUSD 23.86 M
Himadri Chemicals and Industries
Manufactures coal tar and basic industrial chemicals.
1987Kolkata, West Bengal, IndiaUSD 24 MUSD 515.01 M1,161
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Camlin Fine Sciences

CAMLINFINE: Q2 REVENUE 4.91B RUPEES VS 4.6B (YOY)
Exchange Update • 8 days ago
CAMLINFINE: Q2 CONS NET LOSS 279M RUPEES VS LOSS 143.8M (YOY)
Exchange Update • 8 days ago
CAMLINFINE: Q2 EBITDA 22M RUPEES VS 334M (YOY); Q2 EBITDA MARGIN 0.46% VS 7.27% (YOY)
Exchange Update • 8 days ago
Tribhovandas Bhimji Zaveri Ltd leads losers in 'B' group | Capital Market News - Business Standard
Business Standard • 3 months ago
Camlin Fine Sciences Ltd June-Quarter Consol Net Loss 317.1 Million Rupees
Reuters • 3 months ago
CAMLINFINE: Record revenue growth offset by margin compression and exceptional costs in Q1 FY27
Quartr • 3 months ago
CAMLINFINE: Revenue up year-over-year, but net loss driven by exceptional and discontinued items
Quartr • 3 months ago
CAMLINFINE: Revenue up 28% YoY, but margins compressed; H2 margins expected to rebound to 13–15%
Quartr • 3 months ago
French Stock Market Authority Clears CAMLIN FINE SCIENCES' Mandatory Tender Offer For Vinpai Shares
Reuters • 4 months ago
Camlin Fine Sciences March-Quarter Consol Profit At 862.8 Million Rupees
Reuters • 5 months ago
Premium access

Complete news archive for Camlin Fine Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Camlin Fine Sciences

Camlin Fine Sciences was founded in 1931 and raised its 1st funding round 89 years after it was founded.

Camlin Fine Sciences is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Ashish Subhash Dandekar is the CEO of Camlin Fine Sciences, as recorded in our data.

Camlin Fine Sciences has 693 employees.

The primary company behind Camlin Fine Sciences, Camlin Fine Sciences Limited, reported revenue of ₹1,809 Cr for FY 2026, up 6% year on year.

Camlin Fine Sciences (earlier Camlin Fine Chemicals) offers food grade antioxidants for the food and feed market. Camlins main products are TBHQ, BHA and ascorbyl palmitate for fats and oils. Apart, it also has a product range that includes liquid antioxidant blends (synthetics and naturals), food-grade ingredients and industrial antioxidants.

Camlin Fine Sciences offers Xtendra, Nasure, Ezential, adorr, and 2 more products and services.

Yes, Camlin Fine Sciences is publicly traded on NSE under the ticker symbol CAMLINFINE.

Camlin Fine Sciences has made 2 acquisitions, including Dresen, and Vinpai.

Camlin Fine Sciences has 2 investors. Key investors include Infinity Direct Holdings, and Convergent Finance.

Camlin Fine Sciences operates through Camlin Fine Sciences Limited.

The legal entities of Camlin Fine Sciences currently have 14 directors, including Ashish Subhash Dandekar, Nirmal Vinod Momaya, Pradip Manilal Kanakia and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available